AbbVie is eyeing regulatory filings in 2027 for the skin disease drug lutikizumab after clearing multiple endpoints in a late-stage trial, but the results have disappointed some analysts, raising questions about its commercial prospects.
AbbVie’s skin disease drug lessens abscess burden in Phase 3 but falls below expectations